Wednesday, 18 September 2019

Japan News

  • ASKLEP joins Medidata partner program

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 20 Dec, 2012

    Singapore: ASKLEP, a leading Tokyo-based provider of clinical research services, has joined the Medidata Solutions Partner Program as part of its strategy to expand its existing offerings ...Read more

  • Bayer gets Japan's nod for gastro tumor drug

    Japan |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 22 Aug, 2013

    Singapore: Bayer has received Japan's approval for Stivarga indicated for the treatment of patients suffering from gastrointestinal stromal tumor (GIST) who have progressed following prior ...Read more

  • Noven Pharma files NDA with US FDA

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 30 Aug, 2012

    Singapore: Noven Pharmaceuticals, a wholly-owned subsidiary of Japanese firm Hisamitsu Pharmaceutical, has submitted a new drug application (NDA) to the US Food & Drug Administration se...Read more

  • Theravance, Alfa Wassermann collaborate

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 04 Oct, 2012

    Singapore: Theravance and Alfa Wassermann entered into an exclusive development and commercialization agreement in certain countries for velusetrag, Theravance's investigational 5-HT4 agon...Read more

  • Japan's Meiji Seika Pharma buys Medreich

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 27 Jun, 2014

    Singapore: Japan's Meiji Seika Pharma is set to acquire Bangalore-based generic drug maker Medreich for $290 million. The nine-decade-old company has acquired a 75 percent stake held by Med...Read more

  • Scientists in Japan make progress in vaccine against norovirus

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 24 Apr, 2014

    Singapore: Even as a new strain of stomach flu is infecting many across the world, scientists in Japan seem to have made progress in vaccine development. Early stage human studies on a vac...Read more

  • FDA approves Eisai's ACIPHEX

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 24 Apr, 2014

    Singapore: Eisai announced that the US Food and Drug Administration (FDA) has approved ACIPHEX Sprinkle Delayed-Release Capsules 5mg and 10mg for the treatment of Gastroesophageal Reflux ...Read more

  • Takeda establishes global medical affairs dept in Japan

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 26 Nov, 2012

    Singapore: Takeda Pharmaceutical has established the Global Medical Affairs Japan Department at Takeda Development Center Japan's Pharmaceutical Development Division. The company also appo...Read more

  • Zeria gets nod for Acofide Tablets in Japan

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 01 Apr, 2013

    Singapore: Zeria Pharmaceutical and Astellas Pharma announced that, Zeria has obtained the marketing approval of Acofide Tablets 100mg for the treatment of functional dyspepsia (FD) from t...Read more

  • Interphex Japan concludes in Tokyo

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 05 Jul, 2012

    International pharmaceutical R&D and manufacturing conference and expo, the 25th Interphex Japan, concluded on a successful note in Tokyo. Held from June 27 till June 29, at Tokyo Big S...Read more

  • Daiichi to aid drug discovery projects

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 12 Mar, 2013

    Singapore: Daiichi Sankyo has launched TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project for 2013. The company will select research partners for the proj...Read more

  • Shimadzu pharma summit concurs that innovation is the key

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 02 Nov, 2012

    Singapore: The Shimadzu Global Pharma Summit 2012 held in Singapore sent out an unaninmous message that it is high time that pharma firms adopt innovative strategies to churn out new drugs ...Read more

  • Scottish body approves Fycompa by Eisai

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 11 Dec, 2012

    Singapore: Scotland's health technology assessment body, Scottish Medicines Consortium (SMC), has approved Eisai's AMPA receptor antagonist Fycompa (perampanel) as a second-line adjunctive ...Read more

  • Daiichi's comments upset former Ranbaxy owners

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 24 May, 2013

    Singapore: Japanese drugmaker Daiichi Sankyo, which currently holds a majority stake in Ranbaxy, had earlier highlighted that it believes that former shareholders of Ranbaxy concealed and m...Read more

  • Shimadzu launches smart device enabled HPLC system

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 09 Jul, 2014

    Singapore: Japan-based global analytics technology provider, Shimadzu, has launched i-Series of new industry standard HPLCs (High Performance Liquid Chromatograph) systems, with built-in to...Read more

  • Daiichi gets positive results in prasugrel trial

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 18 Mar, 2013

    Singapore: Japanese company Daiichi Sankyo has received positive results for a double-blind randomized phase III trial comparing efficacy and safety of prasugrel hydrochloride 20 mg loading...Read more

  • Takeda, UCL collaborate on brain diseases

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 24 Apr, 2014

    Singapore: UCL (University College London) and Japan based Takeda Pharmaceutical have formed a new research collaboration to identify and validate novel target genes for the treatment of ne...Read more

  • Ospens enters distribution deal with Japanese firm

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 26 Nov, 2012

    Singapore: Canadian company Opsens signed its first major agreement granting distribution and other rights for its OptoWire and OptoMonitor, Opsens' products for measuring fractional flow r...Read more



Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls